Tuesday, June 7, 2022, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Multiple Myeloma

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Continental Ballroom – Section C (Lobby Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Ajai Chari, MD
Professor of Medicine (Hematology and Medical Oncology)
Icahn School of Medicine at Mount Sinai
Director, Clinical Research, Multiple Myeloma Program
Associate Medical Director
The Tisch Cancer Institute Clinical Trials Office
New York, New York

Elizabeth O’Donnell, MD
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts


Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

MODULE 1: Front-Line and Maintenance Treatment Options for Patients with Multiple Myeloma (MM)

  • Published research findings with daratumumab-containing front-line regimens for newly diagnosed MM in patients who are eligible and ineligible for transplant; role of the subcutaneous daratumumab formulation
  • Updated data from the Phase II GRIFFIN study evaluating lenalidomide/bortezomib/dexamethasone (RVD) with daratumumab for transplant-eligible patients with newly diagnosed MM
  • Available data with and current role of minimal residual disease assessment to guide clinical management for patients with MM
  • Design, eligibility criteria and recently presented efficacy and safety findings from the Phase III GMMG-HD7 trial comparing isatuximab in combination with RVD to RVD alone for transplant-eligible patients with newly diagnosed MM; implications for clinical practice
  • Current utility of carfilzomib as a component of up-front therapy; implications of findings from published studies evaluating carfilzomib-based induction therapy
  • Selection of an optimal maintenance approach for transplant-eligible and transplant-ineligible patients, including those receiving daratumumab-containing induction regimens
  • Major clinical trials and real-world data sets with oral ixazomib in the induction and maintenance settings

MODULE 2: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory (R/R) MM

  • Published Phase III research with isatuximab for R/R MM (eg, ICARIA-MM, IKEMA trials); FDA approval, optimal use in clinical practice and ongoing research
  • Key data sets supporting the use of selinexor-based therapy for patients with R/R MM; ongoing studies of selinexor in combination with other agents and in earlier lines of treatment
  • Principal findings with belantamab mafodotin alone and in combination with other systemic therapies for R/R MM; ongoing evaluations and incorporation into routine practice
  • Recent FDA approval of ciltacabtagene autoleucel for R/R MM and safety and efficacy data from the pivotal Phase I/II CARTITUDE-1 study
  • Design, eligibility criteria and updated efficacy and safety results from the pivotal Phase II KarMMa trial evaluating idecabtagene vicleucel for R/R MM
  • Optimal selection of patients for and timing of chimeric antigen receptor (CAR) T-cell therapy for R/R MM
  • Incidence, severity and management of toxicities commonly observed with anti-BCMA-based therapies

MODULE 3: Future Directions in the Management of MM

  • Ongoing studies evaluating the role of CAR T-cell therapy in earlier-stage disease settings (KarMMA-4, CARTITUDE-2)
  • FDA breakthrough therapy designation and promising data with the BCMA-directed bispecific antibody teclistamab for R/R MM in the MajesTEC-1 study; ongoing Phase III studies of teclistamab in combination with other agents in the front-line and R/R settings (MajesTEC-4, MajesTEC-3)
  • Non-BCMA-directed bispecific antibodies (eg, talquetamab, cevostamab) for R/R MM: Mechanism of action, available data, ongoing studies and plans for development
  • Biologic rationale for targeting Bcl-2 in MM; published data with and ongoing investigations of venetoclax-based therapy for patients with MM and t(11;14) or Bcl-2 overexpression
  • Similarities and differences between CELMoDs (eg, iberdomide, CC-92480) and standard immunomodulatory drugs; activity and safety observed with iberdomide and with CC-92480 in patients with heavily pretreated MM
  • Other promising novel agents and strategies in clinical development for MM

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Customize the selection of first-line therapy for individuals with newly diagnosed multiple myeloma (MM), considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM who are eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory MM.
  • Evaluate the role of minimal residual disease assessment for the monitoring and management of patients with MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies, in order to facilitate their integration into MM management algorithms.
  • Evaluate the biologic rationale for the use of chimeric antigen receptor (CAR) T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and identify patients for whom treatment with this novel approach should be considered and/or recommended.
  • Recall available clinical data with novel agents and strategies under investigation for MM, and counsel appropriate patients about clinical trial availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr ChariAdvisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Oncoceutics Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr O'DonnellAdvisory Committee: Bristol-Myers Squibb Company; Consulting Agreements: Bristol-Myers Squibb Company, Janssen Biotech Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc. Dr OrlowskiAdvisory Committee: Amgen Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Clinical Research: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research: BioTheryX Inc, Heidelberg Pharma, Pfizer Inc; Ownership Interest: Asylia Therapeutics Inc (founder with equity interest and director, scientific advisory board).

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room
Continental Ballroom – Section C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of multiple myeloma.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.